Cite
HARVARD Citation
Shah, H. et al. (2022). Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert review of anticancer therapy. 22 (11), pp. 1163-1175. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Shah, H. et al. (2022). Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert review of anticancer therapy. 22 (11), pp. 1163-1175. [Online].